3 results match your criteria dt-tgct

  • Page 1 of 1

The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study.

Orphanet J Rare Dis 2021 Apr 29;16(1):191. Epub 2021 Apr 29.

Department of Orthopaedic Surgery, Leiden University Medical Center, Leiden, The Netherlands.

Background: Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive neoplasm arising from the synovium of joints, bursae, and tendon sheaths affecting small and large joints. It represents a wide spectrum ranging from minimally symptomatic to massively debilitating. Most findings to date are mainly from small, retrospective case series, and thus the morbidity and actual impact of this rare disease remain to be elucidated. Read More

View Article and Full-Text PDF

Management of tenosynovial giant cell tumour of the foot and ankle.

Bone Joint J 2021 Apr;103-B(4):788-794

Department of Orthopaedic Surgery, Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Aims: Tenosynovial giant cell tumour (TGCT) is one of the most common soft-tissue tumours of the foot and ankle and can behave in a locally aggressive manner. Tumour control can be difficult, despite the various methods of treatment available. Since treatment guidelines are lacking, the aim of this study was to review the multidisciplinary management by presenting the largest series of TGCT of the foot and ankle to date from two specialized sarcoma centres. Read More

View Article and Full-Text PDF

Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy.

Expert Rev Anticancer Ther 2020 06 22;20(6):441-445. Epub 2020 Apr 22.

Orthopedic Oncology, IRCCS Istituto Ortopedico Rizzoli , Bologna, Italy.

Introduction: Tenosynovial giant cell tumor (TGCT) is a benign clonal neoplastic proliferation arising from the synovium often causing pain, swelling, joint stiffness, and reduced quality of life. The optimal treatment strategy in patients with diffuse-type TGCT (dt-TGCT) is evolving. Surgery is the main treatment, with a high recurrence rate and surgery-related morbidity. Read More

View Article and Full-Text PDF
  • Page 1 of 1